40results about How to "Trigger immune response" patented technology

The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC).

The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.

The invention provides a p72 fusion protein of an African swine fever virus, and a preparation method and an application thereof, and relates to the technical field of biology. The p72 fusion proteinof the African swine fever virus contains a p72 protein fragment and a GCN4 fragment of the African swine fever virus, wherein the GCN4 fragment has an amino acid sequence of SEQ ID NO. 1. The p72 fusion protein of the African swine fever virus can form a trimer and has good immunogenicity.

The invention discloses a poultry antivirus composition, freeze-dried powder, a preparation method and applications of the composition, and belongs to the technical field of feed additive for poultry and livestock. The poultry antivirus composition is mainly composed of the following components in parts by weight: 90 to 100 parts of poultry antivirus yolk antibody, 1 to 2 parts of poultry antivirus transfer factor, and 1 to 2 parts of alpha-interferon, and preferably also comprises the following components in parts by weight: 5 to 10 parts of astragalus polysaccharide, 5 to 10 parts of angelica polysaccharide, 10 to 20 parts of wolfberry polysaccharide, and 10 to 30 parts of licorice polysaccharide. The poultry antivirus yolk antibody, poultry antivirus transfer factor, alpha-interferon, and traditional Chinese herbal extracts (astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide, and licorice polysaccharide) are compounded to prepare the composition, which can effectively improve the immunity and disease preventing performance of poultry organism and has a good preventing and treating effect on poultry viral diseases. The composition can be made into freeze-dried powder, which can be preserved at a normal temperature for a long time and has the advantages of high antibody titer and good bio-activity.

The invention discloses a Z structural domain derivative of staphylococcus protein A and application thereof. Particularly, the provided Z structural domain derivative of staphylococcus protein A has the capacity for combining IgG, Z structural domain amino acid is mutated to form the Z structural domain derivative, and KZFY / KZ<=10%, wherein KZFY is the combining constant of the Z structural domain derivative and IgG, and KZ is the combining constant of a Z structural domain and IgG; after the Z structural domain derivative is used for immunizing animals, the animals can be induced to generate immunoreaction for staphylococcus protein A. The ZFY derivative and carrier protein DTT are coupled to obtain a kind of protein which can be expressed and purified conveniently, and the protein can effectively stimulate an immune system to generate protein A antibodies.

The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided.

The therapeutic hepatitis B vaccine is liposome containing hepatitis B surface antigen with or without immunoregulation molecule. It may be used to treat chronic hepatitis B caused by HIV infection and to prevent HIV infection. The technological process of inverse phase evaporation and freeze drying to prepare the said vaccine is also provided.

The invention discloses lactobacillus plantarum capable of promoting the secretion of SIgA (Secretory Immunoglobulin A) in an intestinal canal. The lactobacillus plantarum is characterized by being separated from koumiss samples collected in China and is collected at China General Microbiological Culture Collection Center of Microbiological Culture Management Committee, the collection number is CGMCC No. 5468, and the collection date is 18th, November 2011. The invention also discloses a detecting method of the lactobacillus plantarum.

The invention provides a preparation method and application of a bacillus cereus monoclonal antibody. The preparation method comprises the following steps of: 1, preparing bacterial antigen through fixation of bacillus cereus by incubation treatment of paraform; 2, injecting the bacterial antigen so as to avoid emulsification; 3, performing short spacing impulse injection so as to quickly promote immunization; 4, planting solid tumors so as to rejuvenate tumor cells; 5, performing chemical induction and fusion; 6, performing semifluid selection so as to obtain monoclonal hybridoma; 7, performing cooperation of negative screening and positive screening so as to obtain a specific antibody; and 8, using a polyclonal antibody as a capture antibody and using a monoclonal antibody as a detection antibody to establish dual-antibody sandwich ELISA.

The invention discloses a veterinary antivirus composition, freeze-dried powder, a preparation method and applications of the composition, and belongs to the technical field of veterinary feed additive. The veterinary antivirus composition is mainly composed of the following components in parts by weight: 85 to 100 parts of veterinary antivirus yolk antibody, 1 to 5 parts of veterinary antivirus transfer factor, and 1 to 5 parts of alpha-interferon; and preferably also comprises the following components in parts by weight: 5 to 10 parts of astragalus polysaccharide, 5 to 10 parts of angelica polysaccharide, 10 to 20 parts of wolfberry polysaccharide, and 10 to 30 parts of licorice polysaccharide. The veterinary antivirus yolk antibody, veterinary antivirus transfer factor, alpha-interferon, astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide, and licorice polysaccharide are co-used, and thus the composition has the advantages of strong pertinency, high antibody titer, and good bio-activity, is capable of improving the organism immunity and disease preventing ability, and effectively prevents the animal viral diseases.

The hepatitis treating medicine is prepared with Japanese St. Johnswort, Cordate houttuynia, paraglaucous bauhinia, lily and other medicinal materials, which cooperate mutually to kill all the hepatitis viruses, regenerate blood and eliminate toxic matter from body. It has obvious curative effect, high curative rate and reliable performance. The present invention is suitable for being prepared into different forms, such as medicine powder, bolus, effervescent preparation, etc.

The invention provides a preparation method of bacillus cereus polyclonal antibodies, which comprises the following steps: 1, enrichment: coating activated bacillus cereus on a flat plate for enlarge cultivation; 2, fixation: fixing surface compositions of the bacillus cereus by using a modified boiling water bath method, so that antigenic determinants are fully exposed; 3, emulsification: preparing a uniform emulsified liquid from an adjuvant-bacillus mixture by using a self-assembled emulsifier; 4, immunization: carrying out animal immunization in a mode of being based on multiple loca on the back and supplemented by peripheral loca; 5, antiserum titer: evaluating the antiserum titer by using an ELISA method, and carrying out enhanced immunization; 6, taking whole blood: taking whole blood from cervical arteries under the condition of anesthesia by using chloral hydrate; 7, preparation of antiserum: standing the rabbit whole blood at optimum temperature so as to carry out natural chromatography, and carrying out centrifugal separation on the antiserum; and 8, purification: purifying the antiserum by using an n-caprylic acid-ammonium sulfate method, so that a polyclonal antibody is prepared. The polyclonal antibody prepared by using the preparation method disclosed by the invention is high in titer, good in specificity and strong in sensitivity, and has a great application advantage.

The invention discloses a composition for resisting swine fever, a feed additive, and a preparation method and use of the feed additive. The composition comprises, by weight, 95-97 parts of a swine fever-resistant yolk antibody and 0.9-2.1 parts of a swine fever-resistant transfer factor. The feed additive comprises, by weight, 95-97 parts of the swine fever-resistant yolk antibody, 0.9-2.1 parts of the swine fever-resistant transfer factor, 0.01-0.02 parts of an antiseptic, 0.2-0.3 parts of an inactivator, 0.05-0.1 parts of selenium, 0.5-1 part of vitamin C, 1-2 parts of polyvinylpyrrolidone and 0.5-1 part of glycine. Through compounding of the swine fever-resistant yolk antibody and the swine fever-resistant transfer factor, the feed additive can substantially improve swine fever prevention and treatment effects and has the advantages of good specificity, long preservation time at a normal temperature, high antibody titer and good biological activity.

The invention discloses a CCL1-containing fusion protein, a preparation method and application, the fusion protein sequentially comprises an IgE signal peptide, CCL1, a linker and an antigen from an N terminal to a C terminal, or the IgE signal peptide, CCL1, the linker, the antigen and a T2 fragment, and the amino acid sequence of the T2 fragment is shown as SEQ ID NO: 4. According to the invention, different antigen proteins are transferred and crossly presented to the surface of the DC cell by utilizing the chemotactic binding capacity of CCL1 and surface receptors of immune cells such as the DC cell, so that the efficiency of phagocytosis, processing and presentation of various antigen proteins by the DC cell is improved, and the effect of preventing and treating related diseases is improved. Experiments prove that the T2 sequence disclosed by the invention has a very strong immune enhancement effect, and can further excite body fluid and cellular immune response in the process of promoting antigen presentation, so that the effect of inhibiting growth of related tumors is finally achieved.

The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.

The invention discloses a pharmaceutical composition for preventing duck viral diseases, freeze-dried powder, a preparation method, and applications of the composition, and belongs to the technical field of poultry feed additive. The pharmaceutical composition is mainly composed of the following components in parts by weight: 85 to 95 parts of duck viral disease preventing yolk antibody, 1 to 5 parts of duck viral disease preventing transfer factor, and 1 to 5 parts of alpha-interferon, and preferably comprises the following components in parts by weight: 5 to 10 parts of astragalus polysaccharide, 5 to 10 parts of angelica polysaccharide, 10 to 20 parts of wolfberry polysaccharide, and 10 to 30 parts of licorice polysaccharide. The duck viral disease preventing yolk antibody, duck viral disease preventing transfer factor, alpha-interferon, and traditional Chinese medicine extract (astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide, and licorice polysaccharide) are compounded to prepare the pharmaceutical composition, which can prominently improve the organism immunity and disease preventing ability and effectively prevent the duck viral diseases. The pharmaceutical composition can be made into freeze-dried powder, which can be preserved at a normal temperature for a long time and has the advantages of high antibody titer and good bio-activity.

The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.

The invention discloses an epitope based on IL-6 and application of the epitope and particularly provides epitope peptide. The epitope peptide is derived from mammal IL-6 and includes one or more epitopes. The length of the amino acid sequence of the epitope is 2-100% the whole length of the IL-6. The length of the epitope peptide is 3-300 amino acids. Besides, recombinant protein composed of the epitope peptide and carrier protein can induce immune response, to the IL-6, generated by mammals of the same time. The invention further provides fusion protein containing the epitope peptide. The recombinant protein prepared through fusion expression of the epitope peptide and the carrier protein is used and can effectively activate the immune response, to the IL-6, of an organism.

The invention discloses a Chinese herbal medicine preparation for preventing and treating oncorhynchus mykiss enteritis. The Chinese herbal medicine preparation is made of the following raw materials:epimedium herb, hedyotis, Chinese lobelia herb, maple leaf, acalypha australis, plantain herb, heartleaf houttuynia herb, solomonseal rhizome, milkvetch root, perilla leaf, senecio scandens, malayteascurfpea fruit, Tokyo violet herb, Indian bread, glossy privet fruit, corn whisker, and a complex bacterial agent. In the preparation, epimedium herb, maple leaf, acalypha australis, heartleaf houttuynia herb, solomonseal rhizome, milkvetch root, perilla leaf and the like can have sterilization and disinfection effects, plantain herb, senecio scandens and the like can have anti-bacteria and anti-inflammation effects, malaytea scurfpea fruit and Tokyo violet herb can promote the increase of a number of white blood cells in the blood, Indian bread, glossy privet fruit and the like can improve the immunity of fishes, corn whisker and the like have effects similar to an interferon, epimedium herb and the like can promote antibody production, and hedyotis, Chinese lobelia herb and the like canstimulate tumor immune response. Each drug complements each other and promotes each other to achieve prevention and treatment of oncorhynchus mykiss enteritis. The Chinese herbal medicine preparationcontains bacteria that are beneficial to the oncorhynchus mykiss gastrointestinal tract, and intestinal peristalsis is promoted, so that the occurrence of gastrointestinal diseases is reduced.

The invention provides an avian influenza HA-Fd fusion protein as well as a preparation method and a vaccine thereof, and relates to the technical field of biological medicines. The avian influenza HA-Fd fusion protein sequentially contains an avian influenza HA fragment and a bacteriophage Fibritin foldon fragment from an N end to a C end, the amino acid sequence of the avian influenza HA fragment is shown as SEQ ID NO. 1, and the amino acid sequence of the bacteriophage Fibritin foldon fragment is shown as SEQ ID NO. 2. The avian influenza HA-Fd fusion protein has a trimer conformation, andthe protein structure is close to that of natural protein.

The invention relates to a novel bacillus subtilis multi-valent vector-based vaccine and application thereof. The novel bacillus subtilis multi-valent vector-based vaccine comprises a bacillus subtilis recombination strain obtained by using a genetic engineering method, wherein the bacillus subtilis recombination strain is classified and named as bacillus subtilis HT5302 and is preserved in the China Center For Type Culture Collection (CCTCC) with a preservation number of CCTCC No:M2012380. The novel bacillus subtilis multi-valent vector-based vaccine is prepared by using the bacillus subtilis recombination strain as a core. A spore with a surface having no a streptococcus agalactiae 3-glyceraldehyde-phosphate dehydrogenase (GAPDH) protein can be generated through inducing the bacillus subtilis recombination strain, and secretes a fusion protein which formed by cell-penetrating peptide and vibrio anguillarum 3-GAPDH when germinating to form a nutrient cell. The novel bacillus subtilis multi-valent vector-based vaccine has a multi-valent protection function on bacterial diseases such as streptococcicosis, vibriosis, edwardsienosis and aeromonas hydrophila.

The invention discloses an epitope based on IL-6 and application of the epitope and particularly provides epitope peptide. The epitope peptide is derived from mammal IL-6 and includes one or more epitopes. The length of the amino acid sequence of the epitope is 2-100% the whole length of the IL-6. The length of the epitope peptide is 3-300 amino acids. Besides, recombinant protein composed of the epitope peptide and carrier protein can induce immune response, to the IL-6, generated by mammals of the same time. The invention further provides fusion protein containing the epitope peptide. The recombinant protein prepared through fusion expression of the epitope peptide and the carrier protein is used and can effectively activate the immune response, to the IL-6, of an organism.

The invention provides a preparation method and application of a bacillus cereus monoclonal antibody. The preparation method comprises the following steps of: 1, preparing bacterial antigen through fixation of bacillus cereus by incubation treatment of paraform; 2, injecting the bacterial antigen so as to avoid emulsification; 3, performing short spacing impulse injection so as to quickly promote immunization; 4, planting solid tumors so as to rejuvenate tumor cells; 5, performing chemical induction and fusion; 6, performing semifluid selection so as to obtain monoclonal hybridoma; 7, performing cooperation of negative screening and positive screening so as to obtain a specific antibody; and 8, using a polyclonal antibody as a capture antibody and using a monoclonal antibody as a detection antibody to establish dual-antibody sandwich ELISA.

The invention relates to the field of biotechnology, and the invention discloses a use of CCL5. The present invention utilizes the chemotactic binding ability of CCL5 and immune cell surface receptors such as DC cells to transport different antigenic proteins to the surface of DC cells, improves the efficiency of phagocytosis, processing and presentation of various antigenic proteins by DC cells, and improves the efficiency of DC cells. The effect of preventing and treating related diseases. The present invention also adds T2 sequence to the antigen so as to enhance the immune effect.

The invention discloses a veterinary antivirus composition, freeze-dried powder, a preparation method and applications of the composition, and belongs to the technical field of veterinary feed additive. The veterinary antivirus composition is mainly composed of the following components in parts by weight: 85 to 100 parts of veterinary antivirus yolk antibody, 1 to 5 parts of veterinary antivirus transfer factor, and 1 to 5 parts of alpha-interferon; and preferably also comprises the following components in parts by weight: 5 to 10 parts of astragalus polysaccharide, 5 to 10 parts of angelica polysaccharide, 10 to 20 parts of wolfberry polysaccharide, and 10 to 30 parts of licorice polysaccharide. The veterinary antivirus yolk antibody, veterinary antivirus transfer factor, alpha-interferon, astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide, and licorice polysaccharide are co-used, and thus the composition has the advantages of strong pertinency, high antibody titer, and good bio-activity, is capable of improving the organism immunity and disease preventing ability, and effectively prevents the animal viral diseases.

The invention discloses an antiviral composition for poultry, freeze-dried powder, a preparation method and application, and belongs to the technical field of feed additives for livestock and poultry. The antiviral composition for poultry is mainly composed of the following components in parts by weight: 90-100 parts of anti-viral yolk antibody for poultry, 1-2 parts of anti-viral transfer factor for poultry, and 1-2 parts of α-interferon; preferably It also includes the following components in parts by weight: 5-10 parts of astragalus polysaccharide, 5-10 parts of angelica polysaccharide, 10-20 parts of wolfberry polysaccharide, and 10-30 parts of licorice polysaccharide. In the present invention, antiviral egg yolk antibody for poultry, antiviral transfer factor for poultry, α-interferon and traditional Chinese medicine extracts astragalus polysaccharide, angelica polysaccharide, wolfberry polysaccharide and licorice polysaccharide are compounded, which can effectively improve the immunity and disease resistance of poultry bodies Ability to prevent and control poultry viral diseases. After being prepared into freeze-dried powder, it can be stored at room temperature for a long time, and has high antibody titer and good biological activity.

The invention discloses preparation of a neutralizing monoclonal antibody of an anti-hepatitis C virus and application thereof. E2 protein is utilized to strengthen immunity after mice are immunized by pVAX-CpG-N2N8; spleen of the mice with the highest valence aiming at the E2 antibody is taken as an antigen-sensitized B cell and fused with a myeloma cell SP2 / 0 strain, and the fused cell is screened in HAT culture medium, so as to obtain the fused cell, and the fused grows and is cloned to obtain the hybridoma cell strain generating the monoclonal antibody disclosed by the invention. The neutralizing monoclonal antibody of the anti-hepatitis C virus E2 disclosed by the invention is generated by the hybridoma cell strain; epitope combined with the monoclonal antibody is at F550GCTWMNSTGFTKVCGAPPCVIG572 part of E2 glycoprotein. The neutralizing monoclonal antibody of the anti-hepatitis C virus disclosed by the invention has good capability of neutralizing HCV infection, can be used as a hepatitis C virus therapeutic antibody, and has a great application prospect in hepatitis C diagnosis and treatment.